Terms: = Ovarian cancer AND PIK3CA, MGC142161, 5290, ENSG00000121879, P42336, MGC142163, p110-alpha, PI3K AND Prognosis
230 results:
1. Novel prognostic marker TGFBI affects the migration and invasion function of ovarian cancer cells and activates the integrin αvβ3-pi3k-Akt signaling pathway.
Wang H; Xu YH; Guo Y
J Ovarian Res; 2024 Feb; 17(1):50. PubMed ID: 38395907
[TBL] [Abstract] [Full Text] [Related]
2. Complexity of the Genetic Background of Oncogenesis in ovarian cancer-Genetic Instability and Clinical Implications.
Murawski M; Jagodziński A; Bielawska-Pohl A; Klimczak A
Cells; 2024 Feb; 13(4):. PubMed ID: 38391958
[TBL] [Abstract] [Full Text] [Related]
3. HIF-2α-dependent TGFBI promotes ovarian cancer chemoresistance by activating pi3k/Akt pathway to inhibit apoptosis and facilitate DNA repair process.
Ma S; Wang J; Cui Z; Yang X; Cui X; Li X; Zhao L
Sci Rep; 2024 Feb; 14(1):3870. PubMed ID: 38365849
[TBL] [Abstract] [Full Text] [Related]
4. Integrated genomic and transcriptomic analysis reveals the activation of pi3k signaling pathway in HPV-independent cervical cancers.
Wang Y; He M; He T; Ouyang X; Shen X; Shi W; Huang S; Xiang L; Zou D; Jiang W; Yang H
Br J Cancer; 2024 Apr; 130(6):987-1000. PubMed ID: 38253702
[TBL] [Abstract] [Full Text] [Related]
5. MK8722 initiates early-stage autophagy while inhibiting late-stage autophagy via FASN-dependent reprogramming of lipid metabolism.
Wang L; Zhu H; Shi Z; Chen B; Huang H; Lin G; Li J; Yu H; Xu S; Chen G; Ou R; Dai C
Theranostics; 2024; 14(1):75-95. PubMed ID: 38164137
[No Abstract] [Full Text] [Related]
6. Genomic and Molecular Characteristics of ovarian Carcinosarcoma.
Ramphal K; Hadfield MJ; Bandera CM; Hart J; Dizon DS
Am J Clin Oncol; 2023 Dec; 46(12):572-576. PubMed ID: 37986208
[TBL] [Abstract] [Full Text] [Related]
7. CUDC-907 exhibits potent antitumor effects against ovarian cancer through multiple in vivo and in vitro mechanisms.
Wang Y; Wen J; Sun X; Sun Y; Liu Y; Cheng X; Wu W; Liu Q; Ren F
Cancer Chemother Pharmacol; 2024 Apr; 93(4):295-306. PubMed ID: 37938423
[TBL] [Abstract] [Full Text] [Related]
8. Pattern A endocervical adenocarcinomas with ovarian metastasis are indolent and molecularly distinct from destructively invasive adenocarcinomas.
Neil AJ; Li YY; Hakam A; Nucci MR; Parra-Herran C
Histopathology; 2024 Jan; 84(2):369-380. PubMed ID: 37920148
[TBL] [Abstract] [Full Text] [Related]
9. Machine learning developed a pi3k/Akt pathway-related signature for predicting prognosis and drug sensitivity in ovarian cancer.
Han X; Yang L; Tian H; Ji Y
Aging (Albany NY); 2023 Oct; 15(20):11162-11183. PubMed ID: 37851341
[TBL] [Abstract] [Full Text] [Related]
10. m6A-modified circASXL1 promotes proliferation and migration of ovarian cancer through the miR-320d/RACGAP1 axis.
Tian Q; Mu Q; Liu S; Huang K; Tang Y; Zhang P; Zhao J; Shu C
Carcinogenesis; 2023 Dec; 44(12):859-870. PubMed ID: 37738681
[TBL] [Abstract] [Full Text] [Related]
11. High-grade serous ovarian carcinoma, the "Achiles' hill" for clinicians and molecular biologists: a molecular insight.
Bhattacharya R; Ghosh A; Mukhopadhyay S
Mol Biol Rep; 2023 Nov; 50(11):9511-9519. PubMed ID: 37737967
[TBL] [Abstract] [Full Text] [Related]
12. Scoulerine promotes cytotoxicity and attenuates stemness in ovarian cancer by targeting pi3k/AKT/mTOR axis.
Wang F; Zhang Y; Pang R; Shi S; Wang R
Acta Pharm; 2023 Sep; 73(3):475-488. PubMed ID: 37708956
[TBL] [Abstract] [Full Text] [Related]
13. Phellopterin attenuates ovarian cancer proliferation and chemoresistance by inhibiting the PU.1/CLEC5A/pi3k-AKT feedback loop.
Guo A; Lin J; Zhong P; Chen J; Wang L; Lin X; Feng M
Toxicol Appl Pharmacol; 2023 Oct; 477():116691. PubMed ID: 37708916
[TBL] [Abstract] [Full Text] [Related]
14. REG3A promotes proliferation and DDP resistance of ovarian cancer cells by activating the pi3k/Akt signaling pathway.
Jiang L; Liu Y; Liu M; Zheng Y; Chen L; Shan F; Ji J; Cao Y; Kai H; Kang X
Environ Toxicol; 2024 Jan; 39(1):85-96. PubMed ID: 37665173
[TBL] [Abstract] [Full Text] [Related]
15. Pan-cancer Analysis Reveals cancer-dependent Expression of SOX17 and Associated Clinical Outcomes.
Xu LI; Bai Y; Cheng Y; Sheng X; Sun D
Cancer Genomics Proteomics; 2023; 20(5):433-447. PubMed ID: 37643784
[TBL] [Abstract] [Full Text] [Related]
16. Long non-coding RNA SOX21-AS1: A potential tumor oncogene in human cancers.
Lu Z; Xu J; Cao B; Jin C
Pathol Res Pract; 2023 Sep; 249():154774. PubMed ID: 37633003
[TBL] [Abstract] [Full Text] [Related]
17. PAXIP1-AS1 is associated with immune infiltration and predicts poor prognosis in ovarian cancer.
Chen B; Lu X; Zhou Q; Chen Q; Zhu S; Li G; Liu H
PLoS One; 2023; 18(8):e0290031. PubMed ID: 37582104
[TBL] [Abstract] [Full Text] [Related]
18. PTEN deficiency exposes a requirement for an ARF GTPase module for integrin-dependent invasion in ovarian cancer.
Nikolatou K; Sandilands E; Román-Fernández A; Cumming EM; Freckmann E; Lilla S; Buetow L; McGarry L; Neilson M; Shaw R; Strachan D; Miller C; Huang DT; McNeish IA; Norman JC; Zanivan S; Bryant DM
EMBO J; 2023 Sep; 42(18):e113987. PubMed ID: 37577760
[TBL] [Abstract] [Full Text] [Related]
19. Clinical availability and characteristics of multigene panel testing for recurrent/advanced gynecologic cancer.
Kitazawa S; Chiyoda T; Nakamura K; Sakai K; Yoshihama T; Nishio H; Kobayashi Y; Iwata T; Banno K; Yamagami W; Nishihara H; Aoki D
Int J Clin Oncol; 2023 Nov; 28(11):1554-1562. PubMed ID: 37574505
[TBL] [Abstract] [Full Text] [Related]
20. Prognostic impact of molecular profiles and molecular signatures in clear cell ovarian cancer.
Schnack TH; Oliveira DNP; Christiansen AP; Høgdall C; Høgdall E
Cancer Genet; 2023 Nov; 278-279():9-16. PubMed ID: 37567101
[TBL] [Abstract] [Full Text] [Related]
[Next]
